{"transactions":[{"id":4617531,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017."}],"balance_after":15431,"derivative":{"exercise_price":6.05,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617530,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":105.19,"value":241937.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":239258,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617529,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":1817,"price":104.5487,"value":189964.9879,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":241558,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617528,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":8698,"price":103.43,"value":899634.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":243375,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617527,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":30746,"price":102.347,"value":3146760.862,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":252073,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617526,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"sale","planned":true,"acquired":false,"shares":6439,"price":101.7464,"value":655145.0696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":282819,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":4617525,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-14T23:37:32.000Z","date":"2026-09-14","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":6.05,"value":302500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026."}],"balance_after":289258,"source":{"system":"sec-edgar","filing":"0001649904-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1649904/000164990426000026/form4.xml","form_type":"4"}},{"id":730170,"issuer":{"id":4569,"kind":"organization","name":"Kardigan, Inc."},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T23:28:30.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":20706,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share is represented by a restricted stock unit (\"RSU\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date."}],"balance_after":20706,"source":{"system":"sec-edgar","filing":"0001193125-26-277950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000119312526277950/ownership.xml","form_type":"4"}},{"id":749302,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:05.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000119312526257373/ownership.xml","form_type":"4"}},{"id":904823,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-02-13T22:52:16.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":107850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":107850,"derivative":{"exercise_price":98.47,"expiration_date":"2036-02-10","underlying":"Common Stock","underlying_shares":107850},"source":{"system":"sec-edgar","filing":"0001104659-26-015403","document":"tm266366-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926015403/tm266366-6_4seq1.xml","form_type":"4"}},{"id":904822,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-13T22:52:16.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":71900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date."}],"balance_after":71900,"derivative":{"underlying":"Common Stock","underlying_shares":71900},"source":{"system":"sec-edgar","filing":"0001104659-26-015403","document":"tm266366-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926015403/tm266366-6_4seq1.xml","form_type":"4"}},{"id":921295,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:34:37.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":33338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date."}],"balance_after":100012,"derivative":{"underlying":"Common Stock","underlying_shares":33338},"source":{"system":"sec-edgar","filing":"0001104659-26-009768","document":"tm264963-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926009768/tm264963-6_4seq1.xml","form_type":"4"}},{"id":921294,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:34:37.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date."}],"balance_after":42500,"derivative":{"underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001104659-26-009768","document":"tm264963-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926009768/tm264963-6_4seq1.xml","form_type":"4"}},{"id":921293,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-02-03T21:34:37.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":14125,"derivative":{"underlying":"Common Stock","underlying_shares":14125},"source":{"system":"sec-edgar","filing":"0001104659-26-009768","document":"tm264963-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926009768/tm264963-6_4seq1.xml","form_type":"4"}},{"id":921292,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T21:34:37.000Z","date":"2026-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":31522,"price":108.99,"value":3435582.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein."}],"balance_after":239016,"source":{"system":"sec-edgar","filing":"0001104659-26-009768","document":"tm264963-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926009768/tm264963-6_4seq1.xml","form_type":"4"}},{"id":921291,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-03T21:34:37.000Z","date":"2026-02-01","kind":"exercise","planned":false,"acquired":true,"shares":68713,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":270538,"source":{"system":"sec-edgar","filing":"0001104659-26-009768","document":"tm264963-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465926009768/tm264963-6_4seq1.xml","form_type":"4"}},{"id":1111170,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017025086109/ownership.xml","form_type":"4"}},{"id":1120986,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-05T20:16:07.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":false,"shares":43620,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.59,"expiration_date":"2025-11-16","underlying":"Common Stock","underlying_shares":43620},"source":{"system":"sec-edgar","filing":"0001104659-25-056838","document":"tm2517215-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925056838/tm2517215-1_4seq1.xml","form_type":"4"}},{"id":1120985,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-05T20:16:07.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":274,"price":65.6027,"value":17975.1398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.60 to $65.61 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":201825,"source":{"system":"sec-edgar","filing":"0001104659-25-056838","document":"tm2517215-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925056838/tm2517215-1_4seq1.xml","form_type":"4"}},{"id":1120984,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-05T20:16:07.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":43346,"price":65.0431,"value":2819358.2126,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":202099,"source":{"system":"sec-edgar","filing":"0001104659-25-056838","document":"tm2517215-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925056838/tm2517215-1_4seq1.xml","form_type":"4"}},{"id":1120983,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-06-05T20:16:07.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":true,"shares":43620,"price":4.59,"value":200215.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 544 additional shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":245445,"source":{"system":"sec-edgar","filing":"0001104659-25-056838","document":"tm2517215-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925056838/tm2517215-1_4seq1.xml","form_type":"4"}},{"id":1258981,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T02:48:18.000Z","date":"2025-02-16","kind":"exercise","planned":true,"acquired":false,"shares":21250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."}],"balance_after":63750,"derivative":{"underlying":"Common Stock","underlying_shares":21250},"source":{"system":"sec-edgar","filing":"0001104659-25-015322","document":"tm257103-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925015322/tm257103-6_4seq1.xml","form_type":"4"}},{"id":1258980,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2025-02-20T02:48:18.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":200000,"derivative":{"exercise_price":56.69,"expiration_date":"2035-02-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001104659-25-015322","document":"tm257103-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925015322/tm257103-6_4seq1.xml","form_type":"4"}},{"id":1258979,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-20T02:48:18.000Z","date":"2025-02-14","kind":"grant","planned":true,"acquired":true,"shares":133350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date."}],"balance_after":133350,"derivative":{"underlying":"Common Stock","underlying_shares":133350},"source":{"system":"sec-edgar","filing":"0001104659-25-015322","document":"tm257103-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925015322/tm257103-6_4seq1.xml","form_type":"4"}},{"id":1258978,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-20T02:48:18.000Z","date":"2025-02-19","kind":"sale","planned":true,"acquired":false,"shares":9896,"price":57.22,"value":566249.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":201281,"source":{"system":"sec-edgar","filing":"0001104659-25-015322","document":"tm257103-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925015322/tm257103-6_4seq1.xml","form_type":"4"}},{"id":1258977,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-20T02:48:18.000Z","date":"2025-02-16","kind":"exercise","planned":true,"acquired":true,"shares":21250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":211177,"source":{"system":"sec-edgar","filing":"0001104659-25-015322","document":"tm257103-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925015322/tm257103-6_4seq1.xml","form_type":"4"}},{"id":1284040,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2025-02-05T02:25:31.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":28250,"derivative":{"underlying":"Common Stock","underlying_shares":14125},"source":{"system":"sec-edgar","filing":"0001104659-25-009285","document":"tm255457-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925009285/tm255457-3_4seq1.xml","form_type":"4"}},{"id":1284039,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-05T02:25:31.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":4278,"price":59.43,"value":254241.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,475 additional shares acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":189927,"source":{"system":"sec-edgar","filing":"0001104659-25-009285","document":"tm255457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925009285/tm255457-3_4seq1.xml","form_type":"4"}},{"id":1284038,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-05T02:25:31.000Z","date":"2025-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":194205,"source":{"system":"sec-edgar","filing":"0001104659-25-009285","document":"tm255457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465925009285/tm255457-3_4seq1.xml","form_type":"4"}},{"id":1419781,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":4555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 25, 2014. The 4,555 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal quarterly installments thereafter through November 25, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":4555},"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1419780,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":4555,"price":2.9314,"value":13352.527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9100 to $2.9500 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":352489,"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1419779,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":4555,"price":1.43,"value":6513.65,"ownership":{"direct":true},"balance_after":357044,"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1478630,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2024-06-14T20:30:08.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2024. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.77,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-073726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024073726/ownership.xml","form_type":"4"}},{"id":1567722,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-20T00:54:47.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":45494,"price":39.22,"value":1784274.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.04 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":174605,"source":{"system":"sec-edgar","filing":"0001104659-24-036316","document":"tm249308-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924036316/tm249308-4_4seq1.xml","form_type":"4"}},{"id":1628342,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-22T00:03:34.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":259000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":259000,"derivative":{"exercise_price":49.23,"expiration_date":"2034-02-15","underlying":"Common Stock","underlying_shares":259000},"source":{"system":"sec-edgar","filing":"0001104659-24-026162","document":"tm246920-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924026162/tm246920-7_4seq1.xml","form_type":"4"}},{"id":1628341,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-22T00:03:34.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date."}],"balance_after":85000,"derivative":{"underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001104659-24-026162","document":"tm246920-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924026162/tm246920-7_4seq1.xml","form_type":"4"}},{"id":1628340,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-22T00:03:34.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":99000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied."}],"balance_after":220099,"source":{"system":"sec-edgar","filing":"0001104659-24-026162","document":"tm246920-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924026162/tm246920-7_4seq1.xml","form_type":"4"}},{"id":1658334,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2024-02-05T23:53:36.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":false,"shares":14125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":42375,"derivative":{"underlying":"Common Stock","underlying_shares":14125},"source":{"system":"sec-edgar","filing":"0001104659-24-010797","document":"tm245251-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924010797/tm245251-2_4seq1.xml","form_type":"4"}},{"id":1658333,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-05T23:53:36.000Z","date":"2024-02-01","kind":"sale","planned":false,"acquired":false,"shares":4361,"price":45.06,"value":196506.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."}],"balance_after":121099,"source":{"system":"sec-edgar","filing":"0001104659-24-010797","document":"tm245251-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924010797/tm245251-2_4seq1.xml","form_type":"4"}},{"id":1658332,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-05T23:53:36.000Z","date":"2024-02-01","kind":"exercise","planned":false,"acquired":true,"shares":14125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":125460,"source":{"system":"sec-edgar","filing":"0001104659-24-010797","document":"tm245251-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465924010797/tm245251-2_4seq1.xml","form_type":"4"}},{"id":1840873,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2023-06-30T20:00:32.000Z","date":"2023-06-28","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 28, 2023. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":2.27,"expiration_date":"2033-06-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-040287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000120919123040287/doc4.xml","form_type":"4"}},{"id":2032352,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T21:08:31.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":229600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":229600,"derivative":{"exercise_price":27.35,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":229600},"source":{"system":"sec-edgar","filing":"0001104659-23-010490","document":"tm235340-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465923010490/tm235340-4_4seq1.xml","form_type":"4"}},{"id":2032351,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2023-02-03T21:08:31.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":56500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date."}],"balance_after":56500,"derivative":{"underlying":"Common Stock","underlying_shares":56500},"source":{"system":"sec-edgar","filing":"0001104659-23-010490","document":"tm235340-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465923010490/tm235340-4_4seq1.xml","form_type":"4"}},{"id":2216803,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-07-01T20:58:33.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment to the Form 4 originally filed for the reporting person on June 23, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing."}],"balance_after":20000,"derivative":{"exercise_price":2.27,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-040298","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000120919122040298/doc4a.xml","form_type":"4/A","original_submission_date":"2022-06-23"}},{"id":2222789,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2022-06-23T20:59:15.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 23, 2022. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.27,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000120919122038958/doc4.xml","form_type":"4"}},{"id":2401148,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-12T02:33:43.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":510000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were granted on February 9, 2022. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":510000,"derivative":{"exercise_price":6.8,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":510000},"source":{"system":"sec-edgar","filing":"0001104659-22-020892","document":"tm226394-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465922020892/tm226394-4_4seq1.xml","form_type":"4"}},{"id":2663115,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2021-06-17T20:00:29.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 16, 2021. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":20000,"derivative":{"exercise_price":2.25,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-041388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000120919121041388/doc4.xml","form_type":"4"}},{"id":2766035,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-31T20:08:36.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":10000,"price":20.1713,"value":201713.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.03 to $20.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":111335,"source":{"system":"sec-edgar","filing":"0001104659-21-044745","document":"tm2111512-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465921044745/tm2111512-1_4seq1.xml","form_type":"4"}},{"id":2858534,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-16T22:26:31.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were granted on February 11, 2021. The option vests and becomes exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date."}],"balance_after":220000,"derivative":{"exercise_price":30.66,"expiration_date":"2031-02-10","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001104659-21-024406","document":"tm216849-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465921024406/tm216849-1_4seq1.xml","form_type":"4"}},{"id":2972803,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":100.27,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":2972802,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":47.77,"underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":2972801,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":48.85,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":2972800,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":14,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":2972799,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":11.55,"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":2972798,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-20T01:26:35.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":4100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320031763/doc4.xml","form_type":"4"}},{"id":3078590,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T21:16:14.000Z","date":"2020-07-20","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were granted on July 20, 2020. 25% of the shares subject to the option will vest and become exercisable on July 20, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter."}],"balance_after":900000,"derivative":{"exercise_price":22.53,"expiration_date":"2030-07-19","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001104659-20-085305","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465920085305/a4.xml","form_type":"4"}},{"id":3101667,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T22:24:07.000Z","date":"2020-06-13","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-017506","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320017506/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3101666,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T22:24:07.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0000899243-20-017506","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320017506/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3102855,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-22T22:37:25.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":1800,"derivative":{"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0000899243-20-017409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320017409/doc4.xml","form_type":"4"}},{"id":3102854,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T22:37:25.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments after June 18, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3000,"derivative":{"exercise_price":100.27,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-017409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320017409/doc4.xml","form_type":"4"}},{"id":3105142,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T21:26:11.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":18500,"derivative":{"exercise_price":21.37,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001104659-20-074733","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465920074733/a4.xml","form_type":"4"}},{"id":3108544,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-16T22:06:34.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-016685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320016685/doc4.xml","form_type":"4"}},{"id":3108543,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T22:06:34.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":2300,"source":{"system":"sec-edgar","filing":"0000899243-20-016685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320016685/doc4.xml","form_type":"4"}},{"id":3110164,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2020-06-15T21:00:54.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":14210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2020. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":14210,"derivative":{"exercise_price":4.1,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":14210},"source":{"system":"sec-edgar","filing":"0000899243-20-016530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924320016530/doc4.xml","form_type":"4"}},{"id":3481005,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T20:14:22.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":15000,"derivative":{"exercise_price":22.93,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-19-037018","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465919037018/a4.xml","form_type":"4"}},{"id":3487398,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-17T22:57:50.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":2300,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-19-017227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319017227/doc4.xml","form_type":"4"}},{"id":3487397,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T22:57:50.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":6600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":6600,"derivative":{"exercise_price":47.17,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-19-017227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319017227/doc4.xml","form_type":"4"}},{"id":3529317,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":478951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":55918},"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529316,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":869565,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 9, 2019, the Series B Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 9, 2019, the Series B Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 9, 2019, the Series B Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":116375},"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529315,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":95712,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spinnaker Trust as Trustee for Trevi 2014 Irrevocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13271},"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529314,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":192000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trevi 2014 Irrevocable Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":27432},"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529313,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":924880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":128243},"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529312,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"purchase","acquired":true,"shares":11250,"price":10,"value":112500.0,"ownership":{"direct":true},"balance_after":352489,"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529311,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":13271,"ownership":{"direct":false,"nature":"By Spinnaker Trust as Trustee for Trevi 2014 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":341239,"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529310,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":27432,"ownership":{"direct":false,"nature":"By Trevi 2014 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":327968,"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3529309,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T21:03:52.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":300536,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 9, 2019, the Series B Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":300536,"source":{"system":"sec-edgar","filing":"0000899243-19-013262","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319013262/doc4.xml","form_type":"4"}},{"id":3535037,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-08T21:00:45.000Z","date":"2019-05-07","kind":"grant","acquired":true,"shares":23684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 7, 2019, effective upon the pricing of the Issuer's initial public offering. This option is scheduled to vest as to (i) 50% of the underlying shares on the earlier of (A) the first anniversary of the date of grant and (B) the date of the first annual meeting of stockholders of the Issuer held following the date of grant and (ii) the remaining 50% of the underlying shares on the earlier of (A) the second anniversary of the date of grant and (B) the date of the second annual meeting of stockholders of the Issuer held following the date of grant."}],"balance_after":23684,"derivative":{"exercise_price":10,"expiration_date":"2029-05-06","underlying":"Common Stock","underlying_shares":23684},"source":{"system":"sec-edgar","filing":"0000899243-19-012652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924319012652/doc4.xml","form_type":"4"}},{"id":3893511,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-14T20:09:19.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 12, 2018, such that this option is fully exercisable on June 12, 2019. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":11000,"derivative":{"exercise_price":48.85,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-18-016601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924318016601/doc4.xml","form_type":"4"}},{"id":3899590,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T20:06:19.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) 1 year from the date of grant or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":10000,"derivative":{"exercise_price":34.89,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-039179","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465918039179/a4.xml","form_type":"4"}},{"id":4188754,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2017-10-10T20:24:10.000Z","date":"2017-10-10","kind":"exercise","acquired":false,"shares":54525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the number of shares of Series A Preferred held by the Reporting Person on an as-converted to common stock basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects the number of shares of Series A Preferred held by the Reporting Person on an as-converted to common stock basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54525},"source":{"system":"sec-edgar","filing":"0001104659-17-061577","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465917061577/a4.xml","form_type":"4"}},{"id":4188753,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T20:24:10.000Z","date":"2017-10-10","kind":"purchase","acquired":true,"shares":25000,"price":17,"value":425000.0,"ownership":{"direct":true},"balance_after":101335,"source":{"system":"sec-edgar","filing":"0001104659-17-061577","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465917061577/a4.xml","form_type":"4"}},{"id":4188752,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T20:24:10.000Z","date":"2017-10-10","kind":"exercise","acquired":true,"shares":54525,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the \"Series A Preferred\") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration.  The Series A Preferred had no expiration date."}],"balance_after":76335,"source":{"system":"sec-edgar","filing":"0001104659-17-061577","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000110465917061577/a4.xml","form_type":"4"}},{"id":4278663,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-16T20:20:47.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 14, 2017, such that this option is fully exercisable on June 14, 2018. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan)."}],"balance_after":11000,"derivative":{"exercise_price":14,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-17-016571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924317016571/doc4.xml","form_type":"4"}},{"id":4349408,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-19T20:28:57.000Z","date":"2017-04-17","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 48 equal monthly installments with the first installment on May 17, 2017, such that this option is fully exercisable on April 17, 2021. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan)."}],"balance_after":22000,"derivative":{"exercise_price":11.55,"expiration_date":"2027-04-16","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000899243-17-010532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000089924317010532/doc4.xml","form_type":"4"}}]}